HolPro Vision Ltd — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$8,968	1
2024	Research	$12,573	1
2023	Research	$21,806	4
2022	Research	$278,378	12
2021	Research	$35,812	12
2020	Research	$95,678	10
2019	Research	$163,235	10

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $216,708 11 payments
Allergan Inc. $173,124 13 payments
Sight Sciences, Inc. $149,580 6 payments
Bausch Health US, LLC $36,750 12 payments
Oyster Point Pharma, Inc. $29,900 6 payments
Alcon Research LLC $6,888 1 payment
Aerie Pharmaceuticals, Inc. $3,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $173,124 13 payments
A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) $156,463 4 payments
Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) $89,680 4 payments
Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease $59,900 2 payments
Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $38,562 2 payments
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $25,050 4 payments
A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $23,500 4 payments
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects with Presbyopia $14,562 3 payments
A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) $13,250 8 payments
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia $7,120 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.